Cystine‐glutamate antiporter <scp>xCT</scp> as a therapeutic target for cancer
Lin LiuPlatform for Radiation Protection and Emergency Preparedness of Southern Zhejiang, School of Public Health and Management Wenzhou Medical University Wenzhou ChinaRui LiuKey Laboratory of Radiobiology (Ministry of Health), School of Public Health Jilin University Changchun ChinaYi LiuPlatform for Radiation Protection and Emergency Preparedness of Southern Zhejiang, School of Public Health and Management Wenzhou Medical University Wenzhou ChinaGuanghui LiPlatform for Radiation Protection and Emergency Preparedness of Southern Zhejiang, School of Public Health and Management Wenzhou Medical University Wenzhou ChinaQing ChenPlatform for Radiation Protection and Emergency Preparedness of Southern Zhejiang, School of Public Health and Management Wenzhou Medical University Wenzhou ChinaXiaodong LiuPlatform for Radiation Protection and Emergency Preparedness of Southern Zhejiang, School of Public Health and Management Wenzhou Medical University Wenzhou ChinaShumei MaPlatform for Radiation Protection and Emergency Preparedness of Southern Zhejiang, School of Public Health and Management Wenzhou Medical University Wenzhou China
2020en
ABI
Abstract
), a member of the amino acid transporter family, consists of two subunits, light chain xCT and heavy chain 4F2hc. xCT is the cystine/glutamate antiporter solute carrier family 7 member 11 (SLC7A11), which promotes cystine uptake and glutathione biosynthetic, thus protecting against oxidative stress and ferroptosis. Studies have confirmed that xCT is highly expressed in a variety of tumour and is associated with tumour proliferation, invasion, metastasis, drug resistance and ferroptosis, and can be used as a potential target for tumour treatment. This review provides insights into the biological effects of xCT and contribute to the development of new xCT-based strategies.
Identifiers
Citations and references
Cited by 20 references